|
Jul 15
|
KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
|
|
Jul 2
|
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jun 26
|
Pendopharm® and KalVista® Partner to Bring First Oral On-Demand HAE Treatment to Canada
|
|
Jun 26
|
KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada
|
|
Apr 8
|
KalVista licenses commercialisation rights for HAE to Kaken in Japan
|
|
Apr 8
|
KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan
|
|
Mar 12
|
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
|
|
Mar 10
|
KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema
|
|
Feb 21
|
KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
|